World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF KIDNEY CANCER USING SIMILAR MOLECULE - 5-METHOXY-SUNITINIB

Dr. Syed Ahmed Hussain*, Maimuna Fatima, Umaima Batool Osmani, Arshiya Tarannum, Faheem Unnisa, Raheem Unnisa Shaik and Nazneen

ABSTRACT

Aim: The study aims to evaluate the efficacy of 5-Methoxy-sunitinib in reducing kidney cancer cell viability using various cytotoxicity and viability assays. Objective: The primary objective is to assess the dose-dependent cytotoxic effects of 5-Methoxy-sunitinib on kidney cancer cells and to compare its effectiveness to the control compound, Everolimus. Research: Kidney cancer cells were treated with different concentrations (1 µM, 5 µM, 10 µM) of 5-Methoxy-sunitinib. The assays used included the MTT, CellTiter-Glo Luminescent Cell Viability, Alamar Blue, Sulforhodamine B (SRB), and LDH Cytotoxicity assays. The results indicated a consistent decrease in cell viability with increasing concentrations of 5-Methoxy-sunitinib, suggesting a dose-dependent inhibition of cancer cell growth. While all assays showed similar trends, the LDH assay results suggested alternative pathways of cell death at higher concentrations, warranting further investigation. Conclusion: 5-Methoxy-sunitinib demonstrated a strong potential in inhibiting kidney cancer cell proliferation in a dose-dependent manner across multiple assays. These findings highlight its promise as a therapeutic candidate for kidney cancer, though additional research is needed to fully elucidate its mechanism of action and therapeutic profile.

[Full Text Article]   [Download Certificate]